Comparison of fluorescent in situ hybridization HER-2 / neu results on core needle biopsy and excisional biopsy in primary breast cancer

摘要: HER-2/neu status is critical for the therapy breast carcinoma. Fluorescent in situ hybridization gene amplification and immunohistochemical stains protein expression are widely used methods to detect status. Multiple studies have shown fluorescent stain results high concordance rates. To our knowledge, a comparison between core needle biopsy subsequent excisional specimens has not yet been studied. We retrospectively evaluated fluorescence both of 125 patients with invasive carcinoma from 2002 2005. There was complete respect 87% evaluated. Comparison 129 biopsies 131 all showed rate 92%. The same 98%. 260 cases examined 95% concordance. On basis study, we observed that repeating testing by and/or on unreasonable, particular intratumoral heterogeneity, indeterminate/borderline after neoadjuvant chemotherapy.